FINWIRES · TerminalLIVE
FINWIRES

歐洲、中東和非洲地區天然氣市場最新動態:受季節性需求減弱影響,期貨價格回吐週三漲幅

By

-- 週四盤後交易中,歐洲天然氣期貨價格延續跌勢,回吐了前一日的部分漲幅。前一日,受美伊衝突地緣政治訊號惡化的影響,天然氣價格一度飆漲約8%。 荷蘭TTF近月合約下跌1.628%,至每兆瓦時46.10歐元(54.06美元);英國NBP合約下跌1.996%,至每熱量單位113.43便士(1.54美元)。 天然氣價格也已從3月中旬超過每兆瓦時60歐元的高點大幅回落。當時,中東暴力衝突升級和霍爾木茲海峽關閉是推動天然氣價格上漲的主要因素。然而,與2月底的水平相比,荷蘭TTF價格仍然偏高,當時的價格在每兆瓦時20多歐元到30歐元出頭之間。 殼牌執行長瓦埃勒·薩萬警告稱,與衝突相關的石油和液化天然氣供應中斷可能持續數月,甚至可能延續到明年,這將對歐洲在下一個供暖季前補充天然氣庫存構成風險。 歐盟能源監管機構合作署(ACER)表示,如果卡達液化天然氣供應中斷持續到2026年12月,可能導致全球260億立方米的天然氣缺口,並使歐盟現貨液化天然氣需求量上升至約560億立方米,價格影響取決於衝突持續時間。 ACER還表示,與亞洲對靈活液化天然氣貨物的競爭正在加劇,這可能會推高價格,並使歐洲在夏季補充庫存的努力更加複雜。受電力產業需求強勁和天氣轉冷的影響,歐盟天然氣庫存水準在冬季結束後降至30%以下,接近九年來的最低水準。 以目前每月約 110 億立方公尺的液化天然氣進口速度,庫存水準可達到約 80%,但要實現歐盟 90% 的目標,可能需要額外的供應,這可能會對夏季價格造成上行壓力。

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM